Strong Buy Rating for 4D Molecular Therapeutics Backed by Promising WAMD Treatment Efficacy and Safety
4D Molecular Therapeutics Analyst Ratings
Buy Rating for 4D Molecular Therapeutics Based on Promising Phase II Trial Results for 4D-150 Gene Therapy
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
Maintaining Buy Rating on 4D Molecular Therapeutics: 4D-150 Poised for Success With Superior Safety and Efficacy in Wet AMD Treatment
4D Molecular Therapeutics Analyst Ratings
4D Molecular Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Dynavax (DVAX) and Natera (NTRA)
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), 4D Molecular Therapeutics (FDMT) and Sanofi (OtherSNYNF)
4D Molecular Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Revance Therapeutics (RVNC) and CureVac (CVAC)
Barclays Remains a Buy on 4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics Analyst Ratings
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40
4D Molecular Therapeutics Analyst Ratings
RBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)
4D Molecular Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Biogen (BIIB)